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Abstract
Purpose To investigate the hepato-protective properties
and underlying mechanisms of SAMC in a non-alcoholic
fatty liver disease (NAFLD) rat model.
Methods Female rats were fed with a diet comprising
highly unsaturated fat diet (30% fish oil) for 8 weeks to
develop NAFLD with or without an intraperitoneal injec-
tion of 200 mg/kg SAMC three times per week. After
euthanasia, blood and liver samples of rats were collected
for histological and biochemical analyses.
Results Co-treatment of SAMC attenuated NAFLD-
induced liver injury, fat accumulation, collagen formation
and free fatty acids (FFAs). At the molecular level, SAMC
decreased the lipogenesis marker and restored the lipolysis
marker. SAMC also reduced the expression levels of pro-
fibrogenic factors and diminished liver oxidative stress
partly through the inhibition in the activity of cytochrome
P450 2E1-dependent pathway. NAFLD-induced inflam-
mation was also partially mitigated by SAMC treatment via
reduction in the pro-inflammatory mediators, chemokines
and suppressor of cytokine signaling. The protective effect
of SAMC is also shown partly through the restoration of
altered phosphorylation status of FFAs-dependent MAP
kinase pathways and diminished in the nuclear transcrip-
tion factors (NF-jB and AP-1) activity during NAFLD
development.
Conclusions SAMC is a novel hepato-protective agent
against NAFLD caused by abnormal liver functions. Garlic
or garlic derivatives could be considered as a potent food
supplement in the prevention of fatty liver disease.
Keywords S-allylmercaptocysteine  NAFLD  Fibrosis 
Oxidative stress  Inflammation
Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the
forms of chronic liver diseases characterized by hepatic
fibrosis, oxidative stress and inflammation. According to
the histological classifications in clinical diagnosis, the
so-called NAFLD ranges from fat accumulation in the
hepatocytes without obvious fibrosis or inflammation to
severe hepatosteatosis that may progress to cirrhosis and
hepatocellular carcinoma [1]. It is an emerging hepatic
disease with an estimated prevalence of 20–40% in Wes-
tern countries [2]. The molecular mechanism for the initi-
ation and progression of NAFLD is summarized by a
‘‘multi-hit’’ theory, where imbalanced lipid metabolism
and insulin resistance is considered as the first hit to the
liver. When insulin resistance occurs, liver becomes more
vulnerable to hyperinsulinemia-induced ‘‘multi-hit’’ events
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involving the release of reactive oxygen species (ROS),
pro-fibrogenic factors and pro-inflammatory mediators
from impaired organelles. Subsequently, activated hepatic
stellate cells induce excessive accumulation of extracellu-
lar matrix proteins, such as collagen, to cause fibrosis with
concomitant necroinflammation and cell death [3, 4].
S-allylmercaptocysteine (SAMC) is a water-soluble
sulfur compound present in aged garlic extract. Previous
studies have shown that SAMC is effective in inhibiting
cell growth and promoting apoptosis in several cancer cell
lines [5–7]. Moreover, SAMC is also shown to play anti-
oxidative and anti-nitrosative stress roles both in vitro and
in vivo [8]. The hepato-protective effect of SAMC is
exhibited in an acetaminophen-induced liver injury model
and a carbon tetrachloride-induced acute injury model
where SAMC inhibits the activity of cytochrome P450 2E1
(CYP2E1) and reduces oxidative stress released by chem-
ical intoxication [9–11]. However, the protective effects
and underlying mechanisms of SAMC in NAFLD remain
unknown. In this study, we demonstrated that administra-
tion of SAMC in a high-fat diet voluntarily and orally fed
rat model effectively attenuated NAFLD-induced hepatic
injury, fibrosis, oxidative stress and inflammation partly
through free fatty acids (FFAs)-dependent pathways and
nuclear transcription factors.
Materials and methods
Reagents
SAMC pure powder was kindly given by Dr. Patrick
M. T. Ling (Queensland University of Technology, Aus-
tralia) and originally from Wakunaga Co. Ltd (Osaka,
Japan). The purity of the SAMC powder is more than 95%
by HPLC analysis. It does not contain any other garlic
compound such as SAC or allicin. The powder was
dissolved in phosphate-buffered saline containing 10%
L-dextrose and 1% gum Arabic (w/v) at pH 4.5. Murine anti-
nitrotyrosine monoclonal antibody was bought from Zymed
(San Francisco, CA, USA). Rabbit anti-CYP2E1 polyclonal
antibody was purchased from Millipore (Billerica, MA,
USA). Antibody against phosphorylated ERK1/2 at Tyr204
(p-ERK) was bought from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Antibody of total c-Jun was obtained
from BD Biosciences (San Jose, CA, USA). Antibodies of
SOCS3, phosphorylated c-Jun at Ser63 (p-cJun), phos-
phorylated p38 MAPK at Thr180/Tyr182 (p-MAPK), total
p38 MAPK, phosphorylated IjBa at Ser32 (p- IjBa), total
IjBa, phosphorylated MEK1/2 at Ser217/221 (p-MEK),
total MEK1/2, total ERK1/2, phosphorylated JNK at
Thr183/Tyr185 (p-JNK), and total JNK were purchased
from Cell Signaling (Danvers, MA, USA).
Animal experiments
Eight-week healthy female SD rats with body weight
ranging from 180 to 200 g were purchased from the Lab-
oratory Animal Unit (LAU), The University of Hong Kong.
Rats were kept under standard conditions for 3 days before
the start of the experiment with free access to animal chow
and tap water. The animals were divided into four groups
(n = 7 per group) namely: (1) control group; (2) NAFLD
group; (3) SAMC treatment only group (200 mg/kg in
solvent; intraperitoneal injection; three times per week);
and (4) NAFLD and SAMC co-treatment group. The
development of NAFLD in rats, including the recipe and
preparation protocols of diet, was performed based on our
previously described voluntary oral feeding NAFLD ani-
mal model [12, 13]. Instead of oral administration or in a
dietary form, SAMC was intraperitoneally injected to avoid
possible degradation prior to absorption through the
gastrointestinal tract (GIT). The diet consists of 9.3 g AIN-
93MX (Dyets incorporation, Bethlehem, PA), 2.6 g AIN-
93VX (Dyets), 0.5 g choline bitatrate (Dyets), 1.1 g
DL-methione (Bio-serv, Frenchtown, NJ), 57.5 g lactal-
bulmine hydrolysate (Bio-serv), 117.5 g dextrose (Dyets),
36.6 ml fish oil (Sigma) and 4.5 g suspending agent K
(Bio-serv) in per 1,000 ml volume. Regular chow for rat
(PicoLab Rodent Diet 20) was purchased from LabDiet
(LabDiet, Brentwood, MO, USA). The calories of regular
chow were provided by 25% from protein, 13% from fat
and 62% from carbohydrates, while the calories of high-fat
diet were provided by 35% from protein, 30% from fat and
35% from carbohydrates. The optimum dosage of SAMC
was previously shown to be effective in protecting the liver
from hepatic oxidative stress in mice [14]. After 8 weeks,
the rats were euthanized by an overdose of anesthesia
(intraperitoneal injection of 150 mg/kg pentobarbitone
sodium) according to the protocols approved by the
Committee of Animal Use for Research and Teaching at
The University of Hong Kong. The Laboratory Animal
Unit of the University of Hong Kong is fully accredited
by the Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC interna-
tional). Blood and liver samples were collected for further
analysis.
Processing of tissue and blood samples
Serum was collected by centrifugation of whole blood
sample at 1,0009g for 10 min at 4 C and stored at
-80 C. Liver tissue samples were fixed in 10% phos-
phate-buffered formalin, processed for histology and
embedded in paraffin blocks. Five-micrometer tissue sec-
tions were cut and stained with hematoxylin and eosin
(H&E) or Sirius Red for histological analysis under LEICA
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Qwin Image Analyser (Leica Microsystems Ltd., Milton
Keynes, UK). The percentage area of the total amount of
collagen (7 sections for each group) was quantified by the
sum areas of Sirius Red positive staining divided by the
reference field multiplied by 100. The severity of NAFLD
of each group was assessed by using the NAFLD activity
scoring (NAS) system as previously described [15]. The
mean NAS score was calculated for each experimental
group.
Serum alanine aminotransferase (ALT) assay
To evaluate the hepatic injury at the enzymatic level, serum
ALT level was measured by using ALT (SGPT) reagent set
(Teco diagnostics, Anaheim, CA, USA) according to
manufacturer’s instructions.
Free fatty acids (FFAs) assay
To study the effect of SAMC on lipid metabolism, serum
FFAs level of each rat was measured by using Cayman free
fatty acids assay kit (Cayman chemical, Ann Arbor, MI,
USA), and the final results were expressed as lM in the
serum.
Measurement of malondialdehyde (MDA) level
To investigate the possible effects of SAMC on hepatic
lipid peroxidation, levels of the end product of lipid
peroxidation (MDA) in all liver tissue samples were
determined by using a Bioxytech LPO-586TM kit (Oxis
Research, Portland, OR, USA). The reaction product was
measured spectrophotometrically at 586 nm. Standard
curves were constructed using 1,1,3,3-tetraethoxypropane
as a standard. The MDA levels were normalized with
corresponding protein amounts determined by a Bio-Rad
Protein Assay Kit (Bio-Rad, Hercules, CA, USA) and
expressed as percentage against the control level.
RNA extraction and reverse transcription-quantitative
polymerase chain reaction
Total RNA of each rat was extracted from the liver sample
by using illustraTM RNAspin mini kit (GE healthcare, UK).
The preparation of the first-strand cDNA was conducted
following the instruction of the SuperScriptTM First-Strand
Synthesis System (Invitrogen, Calsbad, CA, USA).
The mRNA expression levels of sterol regulatory ele-
ment binding protein-1c (SREBP1c), adiponectin, tumor
necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1b),
inducible nitric oxide synthase (iNOS), cyclooxygenase-2
(COX-2), glutathione peroxidase (GPx), catalase (CAT),
monocyte chemoattractant protein-1 (MCP-1), macrophage
inflammatory protein-2 (MIP-2), KC (murine IL-8 ortho-
log), transforming growth factor-beta1 (TGF-b1), procol-
lagen-1 (PC-1), alpha-smooth muscle actin (a-SMA) and
suppressor of cytokine signaling-3 (SOCS-3) were mea-
sured by Takara SYBR premix Taq quantitative PCR
system (Takara Bio Inc, Shiga, Japan) and in MyiQ2 real-
time PCR machine (Bio-Rad). The primer sequences and
annealing temperatures used in those Q-PCR are listed in
Table 1. All primers were designed by using Primer Pre-
mier 5 (Premier Biosoft, Palo Alto, CA, USA) software
with specificity validation. PCR efficiency of each primer
pair was tested. Parallel amplification of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as the
internal control. Relative quantification was done by using
the 2-DDCt method. The relative expression of the specific
gene to the internal control was obtained and then
expressed as a percentage of the control value in the
figures. All quantitative PCR procedures including the
design of primers, validation of PCR environment and
quantification methods were performed according the
MIQE guideline [16].
Western blot analysis
Cytosolic and nuclear protein extraction of rat liver was
conducted using NE-PER protein extraction system (Pierce
Biotechnology, Rockford, IL, USA) with the addition of
Halt phosphatase inhibitor cocktail (Pierce). Before Wes-
tern blot, protein was diluted and mixed with 29 sample
buffer (0.1 M Tris–HCl, pH 6.8, 20% glycerol, 4%
sodium dodecyl sulfate, 0.2% Bromophenol Blue, 5.25%
b-mercaptoethanol). The mixture was denatured at 99 C
for 5 min and followed by electrophoresis in a 10% poly-
acrylamide gel. The protein was then transferred to an
Immun-BlotTM PVDF Membrane (Bio-Rad) in a TE series
transfer electrophoresis unit (Hoefer Inc., Holliston, MA,
USA). The membrane was then incubated in blocking
buffer (5% non-fat milk powder in TBST, 100 mM Tris–
HCl, pH 7.5, 0.9% NaCl, 0.1% Tween 20) for 1 h followed
by incubation with different primary antibodies in TBST
overnight at 4 C with gentle agitation. On the following
day, the membrane was washed with TBST and incubated
with appropriate secondary antibodies for 2 h at room
temperature. Beta-actin was used as the internal control.
After washing off the unbound antibody with TBST, the
expression of the antibody-linked protein was determined
by an ECLTM Western Blotting Detection Reagents (GE
Healthcare). The optical density of the bands was measured
and quantified by ImageJ software (National Institute of
Health, MD). The ratio of the optical density of the protein
product to the internal control was obtained and was
expressed as a percentage of the control value in the
figures.
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Enzyme-linked immunosorbent assay (ELISA)
measurement
To correlate the mRNA expression with protein expression
of selected target genes in the liver, ELISA measurements
of TNF-a, IL-1b, MCP-1 and TGF-b1 were performed by
using corresponding ELISA development kits from Pepro-
Tech (PeproTech Inc., Rocky Hill, NJ, USA) according to
user instructions.
DNA-binding activity of nuclear factor-jB (NF-jB)
and activator protein-1 (AP-1)
Determination of NF-jB and AP-1 are the major tran-
scription factors in the regulation of inflammation and
oxidative stress. The DNA-binding activity of these factors
was performed by electrophoretic mobility shift assay
(EMSA) using the Gel-Shift Assay Systems from Promega
(Promega, Madison, WI, USA). Briefly, the phosphorylated
and purified consensus NF-jB or AP-1 oligonucleotides
(Promega) with 32P labeling was mixed with 24 lg of
nuclear protein extract and 109 Gel-Shift Binding Buffer
(200 mm Tris–HCl, pH 7.8, 1 m NaCl, 50 mm MgCl2,
10 mm EDTA and 50 mm dithiothreitol). The mixture was
incubated at room temperature for 20 min prior to elec-
trophoresis on a 4% non-denaturing polyacrylamide gel.
Signals on exposed X-ray films were quantified using laser
scanning densitometry. Specificity of NF-jB binding was
confirmed by competition assays and the ability of a
specific antibody to supershift protein-DNA complexes.
Table 1 Primer sequences and
annealing temperatures for
quantitative PCR
A. Temp. annealing temperature
Target gene Direction Primer sequence (50–30) A. Temp. (C)
SREBP1c Forward GGAGCCATGGATTGCACATT 58
Reverse GCTTCCAGAGAGGAGCCCAG
Adiponectin Forward TAAGGGTGACCCAGGAGATG 58
Reverse GGA ACATTGGGGACAGTGAC
TNF-a Forward ATGAGCACAGAAAGCATGATC 62
Reverse TACAGGCTTGTCACTCGAATT
IL-1b Forward CACCTCTCAAGCAGAGCACAG 60
Reverse GGGTTCCATGGTGAAGTCAAC
iNOS Forward CATTGGAAGTGAAGCGTTTCG 58
Reverse CAGCTGGGCTGTACAAACCTT
COX-2 Forward TGTATGCTACCATCTGGCTTCGG 58
Reverse GTTTGGAACAGTCGCTCGTCATC
GPx Forward TCCACCGTGTATGCCTTCTCC 58
Reverse CCTGCTGTATCTGCGCACTGGA
CAT Forward GAGGCAGTGTACTGCAAGTTCC 58
Reverse GGGACAGTTCACAGGTATCTGC
MCP-1 Forward ACCAGCCAACTCTCACTGAAGC 60
Reverse CAGAATTGCTTGAGGTGGTTGTG
MIP-2 Forward AGTGAACTGCGCTCTCAATG 55
Reverse CTTTGGTTCTTCCGTTGAGG
KC Forward CTGTCAGTGCCTGCAGACCA 56
Reverse CCAAGGGAGCTTCAGGGTCA
IL-6 Forward CCGGAGAGGAGACTTCACAG 60
Reverse GGAAATTGGGGTAGGAAGGA
TGF-b1 Forward CTTCAGCTCCACAGAGAAGAACTGC 60
Reverse CACGATCATGTTGGACAACTGCTCC
PC-1 Forward TGCCGTGACCTCAAGATGTGCC 60
Reverse CATCCACAAGCGTGCTGTAGGTG
a-SMA Forward CTGGAGAAGAGCTACGAACTGC 55
Reverse CTGATCCACATCTGCTGGAAGG
SOCS-3 Forward CCTCCAGCATCTTTGTCGGAAGAC 58
Reverse TACTGGTCCAGGAACTCCCGAATG
GAPDH Forward CCTTCATTGACCTCAACTACATGGT 55
Reverse TCATTGTCATACCAGGAAATGAGCT
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In the competition assay, the addition of 100-fold excess of
unlabeled competitor consensus oligonucleotide prevented
binding. To confirm the specificity of NF-jB or AP-1
binding, supershift experiments with p50/p60 antibody
addition or c-Jun antibody addition were performed,
respectively.
Statistical analysis
Data from each group were expressed as means ± SEM.
Statistical comparison between groups was done using the
Kruskal–Wallis test followed by Dunn’s post hoc test to
detect differences in all groups. A p \ 0.05 was considered
to be statistically significant (Prism 5.0, Graphpad soft-
ware, Inc., San Diego, CA, USA).
Results
Since NAFLD is characterized by liver injury and fibrosis,
as well as increased FFAs in the blood, we measured the
effects of SAMC administration along with the NAFLD
development on liver histology, serum ALT and FFAs
levels. NAFLD induced cellular necrosis, inflammation and
collagen accumulation surrounding the centrilobular veins
of the liver (Fig. 1b, f). Co-treatment of SAMC markedly
attenuated the hepatic injury, steatosis, inflammation and
fibrosis without affecting the normal liver cells (Fig. 1d, h).
The percentage of collagen distribution of the liver also
showed a marked reduction in the amount of collagen in
SAMC co-treatment rats, which supported the anti-fibrotic
effects of the SAMC treatment (Fig. 1i). The NAS score of
NAFLD rats was high (5.67 ± 0.49), indicating severe
steatohepatitis after the induction from high-fat diet.
Co-treatment with SAMC significantly reduced the NAS
score to a ‘‘borderline of NASH’’ level (3.42 ± 0.57; Fig. 1j)
[15]. Moreover, serum ALT-indicated lesser injury and
FFAs induced by NAFLD were significantly down-regulated
to control levels by SAMC co-treatment (Fig. 1k, l).
Increased expression of lipogenesis marker gene
(SREBP1c) was observed in the NAFLD rats, whereas the
expression of lipolysis marker gene (adiponectin) was
reduced, suggesting an on-going process of hepatic lipid
accumulation. Addition of SAMC reversed such trend by
down-regulating SREBP1c and up-regulating adiponectin
(Fig. 2a, b).
To further study the effects of SAMC on hepatic fibro-
sis, expression change of key pro-fibrogenic mediators
including TGF-b1, a-SMA and PC-1 were measured by
quantitative PCR or ELISA. NAFLD induced the expres-
sion of TGF-b1 and a-SMA at both transcriptional and
translational levels. When SAMC was co-treated, these
genes were down-regulated and reduced to levels almost
comparable to their corresponding controls (Fig. 2c–e).
The PC-1 mRNA expression in SAMC co-treatment group
also showed significant reduction when compared with
NAFLD rats (Fig. 2f).
To investigate the possible protective function of SAMC
on increased oxidative stress that plays a critical role on the
further development of steatohepatitis, key oxidative stress
markers during NAFLD were measured. Up-regulated
expression of CYP2E1 during NAFLD was counteracted by
SAMC co-treatment (Fig. 3a). Administration of SAMC
also restored the mRNA expression of antioxidant enzymes,
CAT and GPx, which were down-regulated during NAFLD
(Fig. 3b, c). Co-treatment of SAMC also reduced the for-
mation of MDA and nitrotyrosine during NAFLD devel-
opment without disturbing their basal levels (Fig. 3d, e).
Inflammation and subsequent chemoattraction of cell
migration to the liver are critical for the development and
progression of NAFLD [17]. We measured several
inflammatory mediators and chemokines in NAFLD rats
with or without SAMC co-treatment. Consistent with pre-
vious reports, NAFLD induced expressions of pro-inflam-
matory mediators (TNF-a, IL-1b, iNOS, COX-2) (Fig. 4a–f)
and chemokines (MCP-1, MIP-2, KC) (Fig. 5a–d) at both
mRNA and protein levels. Administration of SAMC during
NAFLD development significantly attenuated the inductions
of the expression levels of these inflammatory mediators
when compared to the controls, with values near to control
levels. As the negative regulator of the inflammatory
response, both mRNA and protein expressions of SOCS3
were increased during NAFLD development. Co-treatment
of SAMC also abolished the induced SOCS3 expression
(Fig. 4g, h).
To study the signaling pathway involved in the patho-
physiological processes of NAFLD induced by the eleva-
tion of FFA and the effects of SAMC intervention, we
measured the phosphorylation status and total expression of
MAPK kinases signaling pathways including p38 MAPK,
JNK and MEK/ERK, which play important roles in insulin
and inflammatory responses [18, 19]. Interestingly, our
result showed that an increase in the phosphorylation level
of p38 MAPK and JNK/c-Jun, but a decrease in the
phosphorylation of MEK/ERK1/2 was observed in NAFLD
rat liver tissue. This finding suggested that the MAPK
kinase pathways were differentially regulated during the
development of NAFLD. Co-treatment of SAMC coun-
teracted all the effects of NAFLD induction on the phos-
phorylation of these kinases without influencing the total
expression levels except for total p38 MAPK where it was
reduced by SAMC administration (Fig. 6a–c).
As critical regulators of cellular inflammation, prolifera-
tion and apoptosis, the activity of nuclear transcription factors
NF-jB and AP-1 were induced in NAFLD rats. Co-treatment
of SAMC during NAFLD induction significantly reduced the
Eur J Nutr (2013) 52:179–191 183
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activity of both NF-jB and AP-1, while no obvious effect on
the basal activity of these transcription factors was detected
(Fig. 6d, f). The inhibitory effect of SAMC on the activity
of NF-jB was through the reduction of the elevated
phosphorylation of IjBa and recovery of degraded total
IjBa in the cytosol (Fig. 6d). Supershift assay for NF-jB and
AP-1 were used to confirm the specificities of these assays
(Fig. 6e, g).
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Fig. 1 Ameliorative effects of SAMC on liver injury, collagen accu-
mulation and excessive free fatty acids. Liver H&E staining of a control
group, b NAFLD group, c SAMC group and d NAFLD?SAMC group.
Liver Sirius Red staining of e control group, f NAFLD group, g SAMC
group and h NAFLD?SAMC group. i Percentage of total collagen of
liver with Sirius Red staining, j NAS scoring of liver H&E staining,
k serum ALT level and l serum free fatty acids (FFAs) level of each
group. Magnification: 9200. Data presented are expressed as Mean ±
SEM (n = 7) and experimental groups marked by different letters
represented significant differences between groups at p\ 0.05 (Kruskal–
Wallis test followed by Dunn’s post hoc test). C control, N NAFLD,
S SAMC; N?S NAFLD?SAMC
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Discussion
Common animal models that mimic the initiation and
progression of NAFLD such as in dietary feeding and
genetic manipulation have certain disadvantages. For
example, a high-fat diet model lacks obvious steatohepa-
titis and genetic models (e.g. leptin, agouti, SREBP1c)
often show decreased body weight, cellular fibrosis and
inflammation [20]. The model used in the current study
prevailed over such disadvantages by showing moderate
levels of cellular fibrosis, oxidative stress, necroinflam-
mation and significant increase in body weight (Supple
Fig. 1A). Considering the fat composition in our diet recipe
is closer to the clinical NAFLD fat level of about 30%
when compared to other high-fat diet models (45–75%),
the animal model used in the current study is better suited
and is more physiological for studying the basic patho-
genesis of NAFLD. Addition of SAMC effectively atten-
uated the pathological features of NAFLD in this model
(e.g. hepatic injury, imbalance of lipid metabolism, fibro-
sis, oxidative stress and inflammation) without influencing
the food intake of rats (Suppl. Fig. 1B), suggesting that the
protective effects of SAMC were not simply from the
reduction of food intake or loss of the body weight of rats,
but may be from the direct or indirect actions of SAMC.
According to the ‘‘multi-hit’’ hypothesis, disrupted lipid
metabolism and insulin resistance is the first step toward
NAFLD development. Co-treatment with SAMC not only
reduced the serum FFAs level that may induce the initial
pathological changes during NAFLD [21], but also sig-
nificantly lowered the lipid accumulation within the
hepatocytes (Fig. 1). At the molecular level, this phe-
nomenon was proven by the restoration of the lipid
metabolism-related genes SREBP1c and adiponectin
(Fig. 2). The mechanism whereby excessive FFAs in the
blood induce insulin resistance is partly through the
mediation of protein kinase C, resulting in impaired func-
tion of insulin receptor substrate-1 (IRS-1), which further
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metabolism status and reduced
fibrogenic factors induced by
NAFLD. Expression levels of
a SREBP1c mRNA,
b adiponectin mRNA, c TGF-b1
mRNA, d TGF-b1 protein,
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activates JNK and SOCS3, contributing to insulin resis-
tance [22–24]. In the current study, induced phosphoryla-
tion of JNK and up-regulated level of SOCS3 were
reversed by the administration of SAMC, demonstrating
the effectiveness of SAMC to suppress the process of
FFAs-induced lipid imbalance, which might be one of the
causal factors of insulin resistance (Figs. 3, 6).
In addition to the induction of hyperinsulinemia, exces-
sive FFAs can also trigger the release of ROS and pro-
inflammatory mediators from impaired liver cell organelles,
thus contributing to the subsequent ‘‘hits’’ in the progres-
sion of NAFLD [25]. NAFLD development in our current
model induced the expression of CYP2E1, which mediated
the inhibition of antioxidant enzymes GPx and CAT, as well
as the formation of lipid peroxidation end product (MDA)
and NO metabolism end product (nitrotyrosine), leading to
increased oxidative stress within the cell. Furthermore,
increased inflammatory cytokines and chemokines, which
are partly induced through the activation of NF-jB, further
aggravated NAFLD by enhancing apoptosis and necrosis of
the liver cells [26]. Since increased iNOS is an inducer of
NO production, which takes part in cellular oxidative stress,
there is also a positive feedback loop between oxidative
stress and inflammation during the NAFLD development.
In the current study, administration of SAMC reversed
all these stimulatory processes and inhibitory effects of
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Fig. 3 Ameliorating effects of
SAMC on NAFLD-induced
oxidative stress. Expression of
a cytochrome P450 2E1
(CYP2E1) protein, b CAT
mRNA, c GPx mRNA, d MDA
formation and e nitrotyrosine
formation were measured in rat
liver after NAFLD development
with or without co-treatment of
SAMC by quantitative PCR or
Western blot. Data presented
are expressed as Mean ± SEM
(n = 7) and experimental
groups marked by different
letters represented significant
differences between groups at
p \ 0.05 (Kruskal–Wallis
test followed by Dunn’s
post hoc test). C control,
N NAFLD, S SAMC,
N?S NAFLD?SAMC
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NAFLD on oxidative stress and inflammatory markers,
which further demonstrated SAMC’s potent protective
capability against NAFLD.
Molecules that initiate hepatic fibrosis (e.g. TGF-b1 and
a-SMA) may also be activated by excessive FFAs through
lipid peroxidation or cytokine production [26, 27]. In
addition, activated hepatic Kupffer cells, the direct source
of pro-inflammatory cytokine production, may in turn
activate hepatic stellate cells (HSCs) to synthesize colla-
gen, initiating the process of liver remodeling in the form
of fibrosis and cirrhosis [28]. SAMC treatment not only
attenuated the gene expression levels of TGF-b1 and
a-SMA, but also reduced collagen accumulation around the
centrilobular veins.
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Fig. 4 Anti-inflammation
properties of SAMC during
NAFLD development.
Expression of a TNF-a mRNA,
b TNF-a protein, c IL-1b
mRNA, d IL-1b protein, e iNOS
mRNA, f COX-2 mRNA,
g SOCS3 mRNA and h SOCS3
protein were measured in rat
liver after NAFLD development
with or without co-treatment of
SAMC by quantitative PCR or
ELISA/Western blot. Data
presented are expressed as
Mean ± SEM (n = 7) and
experimental groups marked by
different letters represented
significant differences between
groups at p \ 0.05 (Kruskal–
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To further elaborate the molecular signaling pathways
that link excessive FFAs and pathological events in NA-
FLD influenced by SAMC intervention, we evaluated the
activation of MAPK kinases by phosphor-specific anti-
bodies. It has recently been shown that the blockage of p38
MAPK in endothelial cells can prevent FFAs-induced
insulin resistance through promoting the expression of
PTEN gene or Akt phosphorylation [29]. Other reports also
pointed out that the blockage of p38 MAPK accomplishes
its anti-insulin resistance effect by decreasing both phos-
phorylation and basal expression of IRS1/2 genes [30, 31].
Here, we showed that the phosphorylation of p38 MAPK
was significantly increased in NAFLD rat but decreased
after the co-treatment of SAMC, suggesting the involve-
ment of this kinase during NAFLD development and
SAMC intervention. In addition, the role of JNK/c-Jun
pathway in FFAs-induced insulin resistance is well studied.
In the liver, JNK activity is increased in animal with insulin
resistance. JNK1 knockout mice are resistance to high-fat-
diet-induced insulin resistance [32]. Moreover, activation
of JNK is known to promote inflammatory response and
apoptosis in animal steatohepatitis model [33, 34]. Taken
together, in this study, inhibition of the JNK/c-Jun phos-
phorylation by SAMC treatment not only attenuated the
FFAs-induced insulin resistance, but also contributed to
the reduction of necroinflammation during NAFLD. For
the decrease in the phosphorylations of MEK1/2 and
ERK1/2, our findings were consistent with a previous
report conducted in a methionine-choline deficient (MCD)
mice model [35]. The inhibition of MEK1/2/ERK1/2 and
subsequent increased activity of transcription of AP-1 are
responsible for hepatocyte sensitization to oxidative stress
for cell death induction [35, 36]. Thus, the restoration of
MEK1/2/ERK1/2 and inhibition of AP-1 activity by SAMC
seem to be one of the important effects of SAMC when
exerting its hepato-protective function during NAFLD. It is
worth noting that when compared to the level of control
group, SAMC treatment alone and SAMC ? NAFLD
co-treatment significantly increased the phosphorylation
status of MEK1/2 and ERK1/2 (Fig. 6b). Since activation
of MEK/ERK pathway is essential for the mediation of
cell proliferation [37], the over phosphorylation of these
kinases in the current study may imply the promotion of
liver regeneration during NAFLD progression. Increased
expression of liver regeneration marker gene, IL-6, further
lends support to this hypothesis (Suppl. Fig. 2).
The activation of NF-jB during NAFLD relies mainly
on the degradation of inhibitor of NF-jB, which is IjB.
ROS and pro-inflammatory cytokines initiate the degrada-
tion of IjB [38]. Since NF-jB is the master regulator of
molecules that take part in cellular proliferation, inflam-
mation and apoptosis, then the inhibition of NF-jB by
SAMC during NAFLD might be a critical step for the
prevention of cascading inflammatory response and oxi-
dative stress injury in the liver [5]. In this study, we clearly
demonstrated that the inhibition of NF-jB by SAMC was
through the recovery of cytosolic IjB expression (Fig. 6D).
In conclusion, we have, for the first time, reported the
hepatoprotective effects of garlic-derived SAMC in a
NAFLD rat model in vivo. Such protective effects are
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partly explained through the reduction on excessive FFAs-
dependent pathways, fibrosis, oxidative stress, inflamma-
tion and diminished in the nuclear transcription factors
(NF-jB and AP-1) activity during NAFLD development.
MAPKs also mediated the attenuation of NAFLD patho-
logical events by SAMC. However, the mediators between
SAMC and FFAs has still need to be experimentally
identified and further investigated. Expressional changes of
FFAs, lipid metabolism genes and MAPKs indirectly
indicated the possible improvement of insulin resistance
from SAMC co-treatment. However, direct evidence from
insulin tolerance test and glucose tolerance test on rats are
essential to validate the possible beneficial effects of
SAMC on insulin resistance. In addition, although the
administration method used in the current study is intra-
peritoneal injection, previous study in human showed that
oral administration of SAMC demonstrated its beneficial
effect [39]. Actually, the dose of SAMC (200 mg/kg) used
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is not realistic for human consumption of aged garlic.
However, a study in animal model within a relatively short
period required a higher dose of SAMC in order to dem-
onstrate the possible beneficial effects of SAMC. For
human consumption, a lower dose with long-term con-
sumption of aged garlic may provide similar protective
effects against fatty liver disease [39]. Since garlic is a
common food supplement around the world, we believe
that garlic or its derivatives could be considered as one of
the preventive measures in the treatment strategy of
NAFLD.
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